Since the start of the coronavirus disease 2019 (COVID-19) pandemic in 2020, the global scientific and medical communities have learned important lessons about this disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). As the pandemic unfolded, we were informed about the major risk factors associated with the disease and had a heightened awareness of the disparities given that racial and ethnic minority groups were disproportionately affected (1,2). We witnessed incredible and rapid progress for research advances that led to improved management strategies and development of innovative therapeutics that resulted in significant reduction in morbidity and mortality (3). However, despite the successes, we are continuing to face growing concerns with postacute sequelae of SARS-CoV-2 infection. Specifically, a great concern is the emerging epidemiologic evidence showing increases in the incidence of diabetes in both adults and children following SARS-CoV-2 infection (4–6). Given the increased prevalence and incidence of diabetes that currently exists worldwide and the projections for future years (7), a further increase in global diabetes rates resulting from COVID-19 would be an enormous public health burden. However, despite the reports to date, there remain too many unanswered questions. Thus, this issue of Diabetes Care includes three reports that provide new data that continue to inform on this issue (8–10).
Patiëntvoorbeelden m.b.t. vergoeding
- ten laste van verzekeraar
- geen vergoeding door verzekeraar